Eledon Pharmaceuticals, Inc. (ELDN) Form 10-Q — Aug 13, 2026
Eledon Pharmaceuticals reported a Q2 2026 net loss of $31.6 million and a six-month net loss of $70.7 million, ending the quarter with $88.8 million in cash, equivalents and short-term investments. Management concluded that substantial doubt exists about the company's ability to continue as a going concern, stating existing resources will not fund planned operations for the next 12 months unless it raises additional financing.
Key figures
- Eps
- -0.27 (Q2 2026); -0.59 (H1 2026)
- Total Assets
- 126094000
- Cash Position
- 88800000
- Shares Outstanding
- 81261152
- Working capital
- 81300000
- Accumulated deficit
- 471858000
- Atm program capacity
- 75000000
- Authorized common shares
- 450000000
- Total stockholders equity
- 33013000
- 2025 offering net proceeds
- 53600000
- Warrants outstanding shares
- 48693790
- 2025 offering gross proceeds
- 57500000
- Warrant liabilities fair value
- 40001000
- Potentially dilutive securities
- 27594356
- Total operating expenses h1 2026
- 44050000
- Pre funded warrant shares counted in basic eps
- 33542272
Price after filing
1 day: -4.3%7 days: -4.9%30 days: -24.9%
Close on the filing date to close N calendar days later (from $3.70). Historical, not a forecast.
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.